On September 23, 2025, the U.S. Court of Appeals affirmed a decision of the Patent Trial and Appeal Board (PTAB) holding key patent claims covering Bayer's Xarelto product unpatentable. Wilson Sonsini represented Mylan Pharmaceuticals in the challenge before the PTAB and at the Federal Circuit. 

The Wilson Sonsini team that represented Mylan in this litigation was led by Wendy Devine, who argued before the court, and Rick Torczon, who argued before the PTAB. In addition, the team included Tasha Thomas and Kelsey Catina.